PENMEDIUM SIGNALFINANCIAL10-K

Penumbra reported solid revenue growth and meaningfully improved operating cash flow generation, though cash reserves declined substantially.

The company's core business momentum appears strong with revenue advancing 17.5% and operating cash flow growing notably to $238.7 million, suggesting improved operational efficiency. However, the 42% decline in cash reserves to $186.9 million warrants monitoring, though this may reflect strategic investments or capital allocation decisions rather than operational stress.

Comparing 2026-02-25 vs 2025-02-18View on EDGAR →
FINANCIAL ANALYSIS

Penumbra demonstrated healthy top-line growth with revenue increasing 17.5% to $1.4 billion while maintaining strong gross margins as gross profit expanded 24.8%. The balance sheet strengthened overall with total assets growing 19% and stockholders' equity advancing 24%, though the significant cash decline from $324.4 million to $186.9 million stands out as the primary area requiring investor attention. Operating cash flow performance was particularly encouraging, rising 41.7% and suggesting the business is generating stronger cash returns from its revenue base.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
-42.4%
$324.4M→$186.9M

Cash declined 42.4% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Operating Cash Flow
Cash Flow
+41.7%
$168.5M→$238.7M

Operating cash flow surged 41.7% — exceptional cash generation, highest quality earnings signal.

Current Assets
Balance Sheet
+27.9%
$951.1M→$1.2B

Current assets grew 27.9% — improving short-term liquidity or inventory/receivables build.

Gross Profit
P&L
+24.8%
$755.0M→$942.4M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Stockholders Equity
Balance Sheet
+24%
$1.2B→$1.4B

Equity base grew 24% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Assets
Balance Sheet
+19.1%
$1.5B→$1.8B

Asset base grew 19.1% — expansion through organic growth, acquisitions, or capital deployment.

Revenue
P&L
+17.5%
$1.2B→$1.4B

Revenue growing 17.5% — solid top-line momentum, watch margins for quality of growth.

Current Liabilities
Balance Sheet
+15.7%
$158.3M→$183.1M

Current liabilities rose 15.7% — increased short-term obligations, watch current ratio.

SG&A Expense
P&L
+15.6%
$574.0M→$663.4M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

R&D Expense
P&L
+14.2%
$31.7M→$36.2M

R&D investment increased 14.2% — signals commitment to future product development, though near-term margin impact.

LANGUAGE CHANGES
NEW — 2026-02-25
PRIOR — 2025-02-18
ADDED
As of February 4, 2026, the registrant had 39,243,053 shares of common stock, par value $0.001 per share, outstanding.
Additional information regarding such risks may be found in the section of this Form 10-K entitled Risk Factors, and you should carefully review and consider such risk factors in addition to the above summary.
Since our founding in 2004, we have invested heavily in our product development and commercial expansion that has established the foundation of our global organization.
We have successfully developed, obtained regulatory clearance or approval for, and introduced products into the thrombectomy market since 2007, access market since 2008, embolization market since 2011, and neurosurgical market since 2014.
We sell our products to healthcare providers primarily through our direct sales organization in the United States, most of Europe, Canada, Australia and Singapore, as well as through distributors in select international markets.
+7 more — sign up free →
REMOVED
As of February 4, 2025, the registrant had 38,515,949 shares of common stock, par value $0.001 per share, outstanding.
Since our founding in 2004, we have had a strong track record of organic product development and commercial expansion that has established the foundation of our global organization.
We have successfully developed, obtained regulatory clearance or approval for, and introduced products into the thrombectomy market since 2007, access market since 2008, embolization market since 2011, and neurosurgical market since 2014, and operated in the immersive healthcare market from 2020 until September 2024.
We sell our products to healthcare providers primarily through our direct sales organization in the United States, most of Europe, Canada and Australia, as well as through distributors in select international markets.
We generated revenue of $1,194.6 million, $1,058.5 million and $847.1 million for the years ended December 31, 2024, 2023 and 2022, respectively.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →